TO · REUN.TO
Reunion Neuroscience Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Toronto, ON M5V 2C3
- Website
- fieldtriphealth.com
Price at previous close
$1.42
Market cap 16.64M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2008 | |||||
| 2009 | |||||
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $0.00 | $0.00 |
About Reunion Neuroscience Inc.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.
- CEO
- Gregory T. Mayes
- Employees
- 16
- Beta
- 4.20
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.42) − 1 = — (DCF, example).